Screener
Collegium Pharmaceutical, Inc. COLL Accrued incentive compensation
Accrued incentive compensation at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept coll:AccruedIncentiveCompensationCurrent.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued payroll and related benefits | 5,468 | 3,382 |
| Accrued royalties | 5,265 | 7,987 |
| Accrued bonuses | 4,101 | 9,172 |
| Accrued incentive compensation | 4,098 | 3,714 |
| Liability for cash-settled share-based awards assumed from Ironshore Acquisition | 2,435 | 2,435 |
| Accrued audit and legal | 1,986 | 1,703 |
| Accrued income taxes | 1,138 | 3,297 |
| Accrued other operating costs | 8,891 | 5,171 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s accrued incentive compensation?
- Collegium Pharmaceutical, Inc. (COLL) reported accrued incentive compensation of $4.1M in Q2 2026.
- What does accrued incentive compensation mean?
- Accrued incentive compensation as reported by Collegium Pharmaceutical, Inc. Common Stock.
Ask your AI about Collegium Pharmaceutical, Inc.'s accrued incentive compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude